The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
Open accessAbstract
BACKGROUND: Copanlisib is a pan-class I phosphatidylinositol 3-kinase inhibitor with predominant activity against the α- and δ-isoforms. PATIENTS AND METHODS: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis. RESULTS: Thirty-three patients with indolent lymphoma and 51 with aggressive lymphoma received copanlisib. Follicular lymphoma (48.5%) and peripheral T-cell lymphoma (33.3%) were the most common histologic subtypes. Most patients (78.6%) had received prior rituximab and 54.8% were rituximab-refractory. Median duration of treatment was 23 and 8 weeks in the indolent and aggressive cohorts, respectively (overall range 2-138). Eighty patients were evaluated for efficacy. The objective response rate was 43.7% (14/32) in the indolent cohort and 27.1% (13/48) in the aggressive cohort; median progression-free survival was 294 days (range 0-874) and 70 days (range 0-897), respectively; median duration of response was 390 days (range 0-825) and 166 days (range 0-786), respectively. Common adverse events included hyperglycemia (57.1%; grade ≥3, 23.8%), hypertension (54.8%; grade ≥3, 40.5%), and diarrhea (40.5%; grade ≥3, 4.8%), all generally manageable. Neutropenia occurred in 28.6% of patients (grade 4, 11.9%). Molecular analyses showed enhanced antitumor activity in tumors with upregulated phosphatidylinositol 3-kinase pathway gene expression. CONCLUSION: Intravenous copanlisib demonstrated promising efficacy and manageable toxicity in heavily pretreated patients with various subtypes of indolent and aggressive malignant lymphoma. Subtype-specific studies of copanlisib in patients with follicular, peripheral T-cell, and mantle cell lymphomas are ongoing. This trial is registered with ClinicalTrials.gov number NCT01660451 (Part A).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., Advani, R., Ghielmini, M., Salles, G. A., Zelenetz, A. D., et al. (2016) · Blood · doi:10.1182/blood-2016-01-643569 · Cited by 7,831
Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., Hillmen, P., Keating, M. J., Montserrat, E., Rai, K. R., et al. (2008) · Blood · doi:10.1182/blood-2007-06-093906 · Cited by 3,787
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270 · cited 1×
“[17] for ibrutinib in patients with CLL and small lymphocytic lymphoma.”
BackgroundTargeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
Wilson, W. H., Young, R. M., Schmitz, R., Yang, Y., Pittaluga, S., Wright, G., Lih, C.-J., Williams, P. M., Shaffer, A. L., Gerecitano, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3884 · Cited by 1,113
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314583 · Cited by 1,069
Self-citationWang, M. L., Blum, K. A., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2015) · Blood · doi:10.1182/blood-2015-03-635326 · Cited by 410
Self-citationManagement of adverse events associated with idelalisib treatment: expert panel opinion
Coutré, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O’Brien, S. M., Pagel, J. M., Poleski, M. H., et al. (2015) · Leukemia & Lymphoma · doi:10.3109/10428194.2015.1022770 · Cited by 273
Liu, N., Rowley, B. R., Bull, C. O., Schneider, C., Haegebarth, A., Schatz, C. A., Fracasso, P. R., Wilkie, D. P., Hentemann, M., Wilhelm, S. M., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0993-t · Cited by 258
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., et al. (2014) · Blood · doi:10.1182/blood-2013-11-537555 · Cited by 252
Zelenetz, A. D., Barrientos, J. C., Brown, J. R., Coiffier, B., Delgado, J., Egyed, M., Ghia, P., Illés, Á., Jurczak, W., Marlton, P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30671-4 · Cited by 250
Self-citationPatnaik, A., Appleman, L. J., Tolcher, A. W., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Weiss, G. J., Sachdev, J. C., Chadha, M., Fulk, M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw282 · Cited by 238
Self-citationFlinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., Wagner-Johnston, N. D., Coutre, S. E., Benson, D. M., Peterman, S., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538546 · Cited by 210
de Claro, R. A., McGinn, K. M., Verdun, N., Lee, S.-L., Chiu, H.-J., Saber, H., Brower, M. E., Chang, C. J. G., Pfuma, E., Habtemariam, B., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2225 · Cited by 171
Idelalisib-associated Colitis: Histologic Findings in 14 Patients
Weidner, A.-S., Panarelli, N. C., Geyer, J. T., Bhavsar, E. B., Furman, R. R., Leonard, J. P., Jessurun, J., & Yantiss, R. K. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000522 · Cited by 160
Miller, B. W., Przepiorka, D., de Claro, R. A., Lee, K., Nie, L., Simpson, N. E., Gudi, R., Saber, H., Shord, S. S., Bullock, J. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2522 · Cited by 147
Paul, J., Soujon, M., Wengner, A. M., Zitzmann-Kolbe, S., Sturz, A., Haike, K., Keng Magdalene, K. H., Tan, S. H., Lange, M., Tan, S. Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2016.12.003 · Cited by 146
Iyengar, S., Clear, A. J., Bödör, C., Maharaj, L., Lee, A. R. I., Calaminici, M., Matthews, J., Iqbal, S., Auer, R. L., Gribben, J. G., et al. (2013) · Blood · doi:10.1182/blood-2012-10-460832 · Cited by 123
Erdmann, T., Klener, P., Lynch, J. T., Grau, M., Vočková, P., Molinský, J., Tušková, D., Hudson, K., Polanska, U. M., Grondine, M. R., et al. (2017) · Blood · doi:10.1182/blood-2016-12-758599 · Cited by 109
Mutations of the PIK3CA Gene in Diffuse Large B Cell Lymphoma
Yu, B., Xiaoyan, Z., Zhang, T., Tao, Q., & Daren, S. (2008) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31815d0588 · Cited by 62
Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow
Greenwell, I. B., Flowers, C. R., Blum, K. A., & Cohen, J. B. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1285702 · Cited by 58
Horwitz, S. M., Porcu, P., Flinn, I. W., Kahl, B. S., Sweeney, J., Stern, H. M., Douglas, M., Allen, K. R., Kelly, P. F., & Foss, F. M. (2014) · Blood · doi:10.1182/blood.v124.21.803.803 · Cited by 46
PI3K signaling pathway in normal B cells and indolent B-cell malignancies
Pongas, G. N., & Cheson, B. D. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.11.011 · Cited by 33
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Leonard, J. P., Trneny, M., Izutsu, K., Fowler, N. H., Hong, X., Zhu, J., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00010 · Cited by 434
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Kumar, A., Singh, A. K., Singh, H., Vijayan, V., Kumar, D., Naik, J., Thareja, S., Yadav, J. P., Pathak, P., Grishina, M., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020299 · Cited by 363
Metadata
- Authors
- Dreyling, M., Morschhauser, F., Bouabdallah, K., Bron, D., Cunningham, D., Assouline, S. E., Verhoef, G., Linton, K., Thieblemont, C., Vitolo, U., Hiemeyer, F., Giurescu, M., Garcia-Vargas, J., Gorbatchevsky, I., Liu, L., Koechert, K., Peña, C., Neves, M., Childs, B. H., & Zinzani, P. L.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 28
- Issue
- 9
- Pages
- 2169-2178
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2729141564
- Cited by
- 265
- References
- 23
- FWCI
- 20.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.